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Effect of pirfenidone on cough in patients
with idiopathic pulmonary fibrosis
To the Editor:
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease. In patients with IPF, cough is one
of the most disabling symptoms and is an independent predictor of disease progression [1–3]. Cough in
IPF is often non-responsive to antitussive therapy [4], and studies on cough are scarce and have
unfortunately not yet resulted in effective treatments. Several observations suggest that pirfenidone, an
anti-fibrotic drug, might decrease cough [5, 6]. We aimed to measure objectively the effect of pirfenidone
on cough in patients with IPF and substantial cough. In addition, we assessed the effect of pirfenidone on
subjective cough and quality of life (QoL) measures.
This international, multicentre, prospective, observational study at four sites (The Netherlands, Italy,
France and UK) recruited patients between 2013 and 2016. Treatment-naïve IPF patients aged 40–85 years
with a forced vital capacity (FVC) ⩾50% and corrected transfer factor of the lung for carbon monoxide
(TLCOc) ⩾30%, in whom pirfenidone therapy was about to be initiated according to regular practice, who
had daily IPF-related cough for ⩾8 weeks with a cough score of ⩾40 mm on a 0–100 mm visual analogue
scale (VAS), were eligible for the present study.
Patients underwent baseline 24-h cough recording with the Leicester Cough Monitor (LCM) prior to
starting pirfenidone, and after 4 and 12 weeks of treatment. The LCM is a validated ambulatory cough
monitoring system [7]. Recordings were centrally analysed with automated cough software as previously
described [7]. On the days of cough recording, participants completed the Leicester Cough Questionnaire
(LCQ, a cough-specific health status questionnaire), the VAS cough severity, VAS urge-to-cough, King’s
Brief Interstitial Lung Disease health status questionnaire (K-BILD), the Hospital Anxiety and Depression
Scale (HADS) and the seven-item Generalised Anxiety Disorder screener (GAD-7) [8, 9].
Analyses were performed on the intention-to-treat population. Objective cough frequency data were log
transformed. To assess the effect of pirfenidone on cough over time we used a linear mixed model, which
accounts for missing data [10]. Sensitivity analyses were performed on the per protocol population with a
linear mixed model and paired t-tests. SPSS Statistics version 21.0 and R version 3.2.2 software packages
were used for statistical analysis. The study was approved by the ethics committees of all participating
centres (clinical trials.gov, NCT02009293). All patients provided written informed consent.
Of the 46 patients screened for the study, 43 patients were included. Reasons for exclusion were low TLCOc
and/or VAS scores. 38 patients completed 4 weeks of the study, and 31 completed 12 weeks. Reasons for
dropout included: cessation of pirfenidone because of adverse events (8), logistic reasons (2), change of
proton pomp inhibitor (1) and death (1). The age of the patients was 72±7 (mean±SD); most were men
(33, 77%) and former smokers (34, 79%). Baseline cough counts, questionnaire scores and pulmonary
function tests are shown in table 1.
After 12 weeks of pirfenidone treatment, objective 24-h cough decreased by 34% (95% CI −48% to
−15%) (table 1). An improvement in 24-h cough was observed in 20 out of 27 patients (74%). Sensitivity
analysis showed similar results (data available on request). Subjective cough measures showed consistent
improvements (table 1). No significant changes in disease-specific QoL and anxiety were found. Even at
the earlier time point of 4 weeks, a smaller, but significant effect on cough counts was observed, with a
14% reduction in 24-h cough frequency (95% CI −22% to −6%; p=0.002). At this time point,
improvements in cough were observed in 24 out of 35 patients (69%).
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In this observational study, pirfenidone treatment reduced objective 24-h cough counts and subjective
cough severity, and improved cough-related QoL in patients with IPF. The magnitude of these changes
was clinically meaningful to patients [9].
This study is the first to show a significant improvement in cough by a pharmacologic treatment, using
both objective and subjective measures in IPF patients. Pirfenidone’s anti-fibrotic effect was thought to be
enigmatic, but has recently been linked to the inhibition of GLI transcription factors [5, 11]. Whether this
inhibition relates to the antitussive effect of pirfenidone is unclear. In IPF, increased cough reflex
sensitivity is thought to be a key mechanism that causes cough [4]. Preliminary studies in guinea pigs
show that pirfenidone decreases cough reflex sensitivity [6]; however, its effect on cough reflex sensitivity
in patients with IPF is yet unknown.
Recently, mechanical tissue stretch was shown to activate TGF-β1 and contribute to the development of
pulmonary fibrosis [12]. LESLIE et al. [13] proposed that recurrent stretch injury, caused by pressure
changes during breathing, promotes fibrosis. Cough might be an additional source of mechanical stress,
and could theoretically contribute to a pro-fibrotic feedback loop. This hypothesis, if correct, might
explain why cough independently predicts disease progression [3]. More research is needed to investigate
the potential role of cough as a driver of disease progression in IPF, as this might have therapeutic
implications.
Only patients with a VAS cough score ⩾40 mm were included in our trial, likely accounting for the higher
cough frequencies we found, compared to those reported by KEY et al. [2] (median cough/h: 23 versus 9.4).
The pattern of higher daytime cough frequency was similar to that of other studies in IPF and chronic
cough [2]. Inhibition of cough by cortical pathways and higher thresholds of peripheral nerves at night, in
addition to less exposure to stimuli that induce cough, might account for this pattern.
Although the treatment of gastroesophageal reflux disease (GERD) reportedly does not affect cough, the
current study required patients with GERD to be on a proton pump inhibitor and remain on a stable dose
[14]. We found no significant changes in K-BILD scores, which is likely due to the fact that the K-BILD
assesses general QoL issues related to IPF and not specific symptoms. Depression scores, but not anxiety,
increased after 12 weeks of treatment; however, the score remained below the cut-off of eight indicating
signs of depression. Therefore, the clinical relevance of this finding remains unclear.
Studies evaluating antitussive treatment in IPF are scarce. HORTON et al. [15] found that thalidomide
improved cough-specific QoL in IPF patients, although no objective cough measurements were assessed.
TABLE 1 Effect of 12 weeks of pirfenidone treatment on objective and subjective cough and
health status measures, analysed with a linear mixed model
Baseline At 12 weeks Change# (95% CI) p-value#
Subjects n 43 31
24-h cough 520 (91 to 3394) 392 (75 to 1746) −34% (−48 to −15%) 0.002
Coughs per hour 23 (4 to 141) 17 (3 to 73) −35% (−49 to −17%) <0.001
Daytime 28 (5 to 171) 20 (4 to 121) −33% (−47 to −14%) 0.003
Night-time 7.2 (0.7 to 101) 3.3 (0 to 54) −34% (−54 to −5%) 0.029
LCQ 12±4 15±4 2.0 (1.0 to 3.0)¶ <0.001
VAS cough 67±15 47±27 −19 (−28 to −10) <0.0001
VAS urge-to-cough 68±16 49±25 −18 (−26 to −10) <0.0001
K-BILD total 50±22 55±23 3.4 (−2.3 to 9.1) 0.245
HADS anxiety 8.5±4 8.5±4 0.7 (−0.6 to 1.9) 0.291
HADS depression 4.7±3 6.0±3 1.6 (0.5 to 2.6) 0.004
GAD-7 5.8±6 5.9±6 0.7 (−0.9 to 2.3) 0.396
FVC % pred 78±15 79±17
TLCOc % pred 51±13 51±16
Data are presented as median (range) or mean±SD, unless otherwise stated. For the Leicester Cough
Questionnaire (LCQ) and the King’s Brief Interstitial Lung Disease health status questionnaire (K-BILD), a
higher score indicated better disease-specific quality of life/cough-related quality of life. For all other
variables, a higher score indicated worse cough frequency/(urge-to-)cough/anxiety/depression. VAS: visual
analogue scale; HADS: Hospital Anxiety and Depression Scale; GAD-7: Generalised Anxiety Disorder
seven-item scale; FVC: forced vital capacity; % pred: % predicted; TLCOc: corrected transfer factor of the
lung for carbon monoxide. #: analysed using a linear mixed model, change in %, points or mm; ¶: minimal
clinical important difference for chronic cough is 1.3.
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Furthermore, thalidomide is known to have a toxic side-effect profile. In six IPF patients in an
uncontrolled study, high dose oral corticosteroids improved cough, but not cough-related QoL [4].
Moreover, immunosuppression has been associated with deleterious effects in IPF. To date, no studies have
assessed the effect of the anti-fibrotic drug nintedanib on cough. Our study results might imply that
pirfenidone is preferable for treatment of IPF patients with cough; however, it would be valuable to
compare the effects of nintedanib and pirfenidone on cough.
Our study has some limitations. As the study was not controlled, the impact of a placebo is not known.
When this study was designed, pirfenidone had been just recently made available. This created high
expectations, and therefore patients, physicians and the ethics committee considered it unethical at the
time to deny patients pirfenidone treatment for 12 weeks, a decision that might be viewed differently
nowadays. The only placebo-controlled pharmacologic study in IPF that used objective cough as an
outcome, showed no placebo effect [16]. We therefore believe that the outcomes of our study are not
significantly influenced by a placebo effect, which is further supported by the already significant, though
smaller effect on cough after 4 weeks of treatment. Furthermore, we included IPF patients with a VAS
score of ⩾40 mm. Therefore, we do not know the effect of pirfenidone on IPF patients with mild cough.
Lastly, our study had a short follow-up period. The long-term effect of pirfenidone on cough in patients
with IPF is therefore unknown; however, our results suggest that the effect of treatment on IPF cough
could be explored in 12-week trials.
In conclusion, in patients with IPF, pirfenidone treatment significantly reduces objective 24-h cough
counts by 34%, and improves subjective measures of cough. These results are clinically meaningful to
patients. More research is warranted into the mechanisms and management of cough in IPF and other
fibrotic diseases.
Mirjam J.G. van Manen1, Surinder S. Birring2, Carlo Vancheri3, Virginia Vindigni3, Elisabetta Renzoni4, Anne-
Marie Russell4,5, Monique Wapenaar1, Vincent Cottin 6 and Marlies S. Wijsenbeek1
1Dept of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. 2Division of Asthma,
Allergy and Lung Biology, King’s College London, London, UK. 3Dept of Clinical and Experimental Medicine, Section
of Respiratory Disease, University of Catania, Catania, Italy. 4Interstitial Lung Disease Unit, Royal Brompton Hospital,
London, UK. 5National Heart and Lung Institute, Imperial College London, London, UK. 6Dept of Respiratory
Medicine, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
Correspondence: Marlies S. Wijsenbeek, Dept of Respiratory Medicine, Erasmus University Medical Center, Rotterdam,
The Netherlands. E-mail: m.wijsenbeek-lourens@erasmusmc.nl
Received: Jan 13 2017 | Accepted after revision: July 17 2017
Support statement: The study was funded by an unrestricted investigator-initiated grant from InterMune/Roche. The
funding source had no input in the design, data collection and analysis and writing of the manuscript, or in the decision
to submit the manuscript for publication. Funding information for this article has been deposited with the Crossref
Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
Acknowledgements: The authors thank Marion Durand (Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France),
Marjolein Gerrits (Erasmus University Medical Center, Rotterdam, The Netherlands) and Claire Wood (King’s College
London, London, UK) for clinical research assistance, and Daan Nieboer (Erasmus University Medical Center) for
statistical support. Author contributions: S.S. Birring, C. Vancheri, V. Cottin and M.S. Wijsenbeek designed the study.
M.J.G. van Manen, C. Vancheri, V. Vindigni, E. Renzoni, A. Russell, V. Cottin and M.S. Wijsenbeek were involved in
data collection. M.J.G. van Manen, S.S. Birring, M. Wapenaar and M.S. Wijsenbeek performed data analyses. M.J.G. van
Manen and M.S. Wijsenbeek drafted the manuscript. All authors interpreted the data and worked collaboratively to
review and prepare the final article.
References
1 Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). The voice of the
patient; a series of reports from the U.S. Food and Drug Administration’s (FDA’s) Patient-Focused Drug
Development Initiative. Idiopathic Pulmonary Fibrosis. March 2015. www.fda.gov/downloads/ForIndustry/
UserFees/PrescriptionDrugUserFee/UCM440829.pdf Date last updated: March 2015. Date last accessed: January
2017.
2 Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough 2010; 6: 4.
3 Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011;
16: 969–975.
4 Hope-Gill BDM, Hilldrup S, Davies C, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J
Respir Crit Care Med 2003; 168: 995–1002.
5 Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a
subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011; 12:
143.
https://doi.org/10.1183/13993003.01157-2017 3
RESEARCH LETTER | M.J.G. VAN MANEN ET AL.
6 Okazaki A, Ohkura N, Fujimura M, et al. Effects of pirfenidone on increased cough reflex sensitivity in guinea
pigs. Pulm Pharmacol Ther 2013; 26: 603–608.
7 Birring SS, Fleming T, Matos S, et al. The Leicester Cough Monitor: preliminary validation of an automated cough
detection system in chronic cough. Eur Respir J 2008; 31: 1013–1018.
8 Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King’s Brief Interstitial Lung Disease
(K-BILD) health status questionnaire. Thorax 2012; 67: 804–810.
9 Raj AA, Pavord DI, Birring SS. Clinical cough IV: what is the minimal important difference for the Leicester
Cough Questionnaire? Handb Exp Pharmacol 2009; 187: 311–320.
10 Chakraborty H, Gu H. A mixed model approach for intent-to-treat analysis in longitudinal clinical trials with
missing values. RTI Press 2009; MR-0009-0903: 1–10.
11 Didiasova M, Singh R, Wilhelm J, et al. Pirfenidone exerts antifibrotic effects through inhibition of GLI
transcription factors. FASEB J 2017; 31: 1916–1928.
12 Froese AR, Shimbori C, Bellaye PS, et al. Stretch-induced activation of transforming growth factor-beta1 in
pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 84–96.
13 Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the
aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med 2012; 136: 591–600.
14 Kilduff CE, Counter MJ, Thomas GA, et al. Effect of acid suppression therapy on gastroesophageal reflux and
cough in idiopathic pulmonary fibrosis: an intervention study. Cough 2014; 10: 4.
15 Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary
fibrosis: a randomized trial. Ann Intern Med 2012; 157: 398–406.
16 Birring SS, Wijsenbeek MS, Agrawal S, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in
idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
Lancet Respir Med 2017; 5: 806–815.
Copyright ©ERS 2017
This ERJ Open article is open access and distributed under the terms of the Creative Commons Attribution Non-commercial Licence 4.0
https://doi.org/10.1183/13993003.01157-2017 4
RESEARCH LETTER | M.J.G. VAN MANEN ET AL.
